Advanced malignant melanoma: survival more likely if treated at a high-volume facility

  • Tella SH & al.
  • J Natl Compr Canc Netw
  • 1 Nov 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • High facility volume is associated with improved OS in patients with stage III/IV cutaneous malignant melanoma.

Why this matters

  • Studies of the potential association between facility volume and outcomes for advanced cancer have shown conflicting results, but this study shows a clear survival benefit for these patients.

Key results

  • In patients with stage III disease, treatment at an intermediate- or low-volume facility was associated with increased risk of death compared with treatment at a high-volume facility (HR, 1.15; 95% CI, 1.09-1.20 and 1.23; 95% CI, 1.17-1.29, respectively).
  • In patients with stage IV disease, treatment at an intermediate- or low-volume facility was associated with increased risk of death compared with treatment at a high-volume facility (HR, 1.16; 95% CI, 1.10-1.21 and 1.29; 95% CI, 1.23-1.36, respectively).
  • In patients with stage IV disease, treatment at a high-volume facility was associated with increased likelihood of receiving chemotherapy and/or immunotherapy compared with treatment at a low-volume facility (P<.0001 for both>

Study design

  • 40,676 patients with stage III/IV malignant melanoma from the National Cancer Database were included.
  • Funding: None disclosed.

Limitations

  • Retrospective study of large database.